Amgen Overview
- Founded
-
1980

- Status
-
Public
- Employees
-
30,010

- Stock Symbol
-
AMGN

- Investments
-
65
- Share Price
-
$245.17
- (As of Friday Closing)
Amgen General Information
Description
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Contact Information
- One Amgen Center Drive
- Thousand Oaks, CA 91320-1799
- United States
Amgen Stock Performance
(As of Friday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$245.17 | $246.53 | $214.39 - $296.67 | $131B | 534M | 2.76M | $12.18 |
Amgen Financials Summary
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
---|---|---|---|---|
EV | 167,365,243 | 167,365,243 | 151,375,930 | 155,779,207 |
Revenue | 26,323,000 | 26,323,000 | 25,979,000 | 25,424,000 |
EBITDA | 8,752,000 | 8,752,000 | 11,142,000 | 12,835,000 |
Net Income | 6,552,000 | 6,552,000 | 5,893,000 | 7,264,000 |
Total Assets | 65,121,000 | 65,121,000 | 61,165,000 | 62,948,000 |
Total Debt | 38,945,000 | 38,945,000 | 33,309,000 | 32,986,000 |
Amgen Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Amgen Comparisons
Industry
Financing
Details
Amgen Competitors (8)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Biogen | Formerly VC-backed | Cambridge, MA | 0000 | 000.00 | 000000&0 | |
000000000 00000000 | Formerly VC-backed | Tarrytown, NY | 00000 | 00000 | 00000000000 | 00000 |
000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
0000000 | Formerly VC-backed | Boston, MA | 0000 | 000000&0 | ||
000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 |
Amgen Patents
Amgen Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
JP-2022023979-A | Imaging system for counting and measuring size of particles in container filled with fluid | Pending | 04-Nov-2021 | 0 | |
US-20220409817-A1 | Syringes, assemblies, and methods of manufacture | Pending | 23-Jun-2021 | 000000000 | |
US-20220401650-A1 | Drug delivery device having shock absorber | Pending | 17-Jun-2021 | 0000000000 | |
US-20220402985-A1 | Engineered nrg-1 variants with improved selectivity toward erbb4 but not against erbb3 | Pending | 10-Jun-2021 | 0000000000 | |
US-20220403037-A1 | Anti-ccr8 antibodies and uses thereof | Pending | 04-Jun-2021 | C07K16/2866 |
Amgen Executive Team (92)
Amgen Board Members (22)
Name | Representing | Role | Since |
---|---|---|---|
000 00000 | Self | Board Member | 000 0000 |
00000 000000 00 | Self | Board Member | 000 0000 |
0000000 000000 00. | Self | Board Member | 000 0000 |
00000 0000000 | Self | Board Member | 000 0000 |
0000 0000000 | Amgen | Board Member | 000 0000 |
Amgen Signals
Amgen Investments & Acquisitions (65)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0000000 00000 | 12-Dec-2022 | 0000000000 | 000.00 | Pharmaceuticals | 000000 00 |
000000000000 | 20-Oct-2022 | 0000000000 | 00.00 | Pharmaceuticals | 000000 00 |
0000000 | 11-Oct-2022 | 00000 0000 | 00000 | Drug Discovery | |
000000 000000 | 20-Jul-2022 | 00000 0000 | 0000 | Biotechnology | |
TeneoBio | 19-Oct-2021 | Merger/Acquisition | 00.00 | Biotechnology | 00000 000 |
Amgen Subsidiaries (8)
Company Name | Industry | Location | Founded |
---|---|---|---|
Amgen Astellas BioPharma | Drug Discovery | Tokyo, Japan | 2013 |
00000 00000000 | Corporate Venture Capital | Thousand Oaks, CA | 0000 |
00000 000000 000 0 | Foundation | Lenexa, KS | 0000 |
000000000000 | Pharmaceuticals | Mountain View, CA | 0000 |
000000 00000000 | Biotechnology | Reykjavik, Iceland | 0000 |
Amgen ESG
Risk Overview
Risk Rating
Updated January, 28, 2023
21.92 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,638
Rank
Percentile

Pharmaceuticals
Industry
00 of 1,008
Rank
Percentile

Biotechnology
Subindustry
00 of 465
Rank
Percentile

Amgen Exits (16)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000000 | 25-Nov-2020 | 00 000000000000000 | 00000 | Completed |
|
00000000 | 23-May-2019 | 00000 | 0000 | Completed |
|
000000 00000000 00 | 18-Oct-2018 | 000000000 | 000.00 | Completed |
|
00000000 | 04-Oct-2017 | 00000 00000 00 | 0000 | Completed |
|
Akili Interactive | 20-Jul-2016 | Early Stage VC | 000.00 | Completed |
|